Kresken M - Search Results

1

In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany.

Kresken M, Wohlfarth E, Weikel C, Butler D, Pfeifer Y, Werner G; ‘Antimicrobial Resistance’ Study Group of the Paul Ehrlich Society for Infection Therapy. Kresken M, et al. J Antimicrob Chemother. 2022 Dec 7:dkac406. doi: 10.1093/jac/dkac406. Online ahead of print. J Antimicrob Chemother. 2022. PMID: 36474310

2

[Multiresistant pathogens--a challenge for clinicians].

Lode HM, Stahlmann R, Kresken M. Lode HM, et al. Among authors: kresken m. Zentralbl Chir. 2013 Oct;138(5):549-53. doi: 10.1055/s-0033-1350885. Epub 2013 Oct 22. Zentralbl Chir. 2013. PMID: 24150804 Review. German.

3

[Surveillance of antibiotic consumption : clarification of the "definition of data on the nature and extent of antibiotic consumption in hospitals according to § 23 paragraph 4 sentence 2 of the IfSG"].

Schweickert B, Kern WV, de With K, Meyer E, Berner R, Kresken M, Fellhauer M, Abele-Horn M, Eckmanns T. Schweickert B, et al. Among authors: kresken m. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Jul;56(7):903-12. doi: 10.1007/s00103-013-1764-8. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013. PMID: 23807401 German.

4

[How effective are linezolid and telithromycin? The resistance situation of pathogenic gram positive infections in Germany].

Kresken M. Kresken M. Pharm Unserer Zeit. 2004;33(1):20-7. doi: 10.1002/pauz.200400051. Pharm Unserer Zeit. 2004. PMID: 14968709 Review. German. No abstract available.

5

Antibiotic sensitivity of Streptococcus pneumoniae isolated from normally sterile body sites: first results of a multicenter study in Germany.

Reinert RR, Queck A, Kaufhold A, Kresken M, Lütticken R. Reinert RR, et al. Among authors: kresken m. Infection. 1994 Mar-Apr;22(2):113-4. doi: 10.1007/BF01739017. Infection. 1994. PMID: 8070922 No abstract available.

6

In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae.

Reinert RR, Kresken M, Mechery V, Lemperle M, Lütticken R. Reinert RR, et al. Among authors: kresken m. Eur J Clin Microbiol Infect Dis. 1998 Sep;17(9):662-5. doi: 10.1007/BF01708352. Eur J Clin Microbiol Infect Dis. 1998. PMID: 9832271

7

Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections--an open multicentre trial.

Bork K, Brauers J, Kresken M. Bork K, et al. Among authors: kresken m. Br J Clin Pract. 1989 Aug;43(8):284-8. Br J Clin Pract. 1989. PMID: 2516463 Clinical Trial.

8

[On the contribution of F. Daschner: "Faulty use of antibiotics and the development of resistance" in Internist, volume 29, issue 5, May 1988, p. 345-6].

Kresken M. Kresken M. Internist (Berl). 1989 Mar;30(3):216-8. Internist (Berl). 1989. PMID: 2654064 German. No abstract available.

9

[Resistant bacteria in Germany. How great are the dangers?].

Kresken M. Kresken M. Kinderkrankenschwester. 2003 Dec;22(12):532-7. Kinderkrankenschwester. 2003. PMID: 16134691 Review. German. No abstract available.

10

[Bacterial resistance in Germany. How great is the danger?].

Kresken M. Kresken M. Med Monatsschr Pharm. 2003 Feb;26(2):38-44. Med Monatsschr Pharm. 2003. PMID: 12619522 German. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters